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Dendritic cells (DC) are key regulators of both innate and adaptive immunity, and the
array of immunoregulatory functions exhibited by these cells is dictated by their differ-
entiation, maturation, and activation status. Although a major role for these cells in the
induction of immunity to pathogens has long been appreciated, data accumulated over
the last several years has demonstrated that DC are also critical regulators of anti-tumor
immune responses. However, despite the potential for stimulation of robust anti-tumor
immunity by DC, tumor-altered DC function has been observed in many cancer patients
and tumor-bearing animals and is often associated with tumor immune escape. Such dys-
function has significant implications for both the induction of natural anti-tumor immune
responses as well as the efficacy of immunotherapeutic strategies that target endogenous
DC in situ or that employ exogenous DC as part of anti-cancer immunization maneuvers.
In this review, the major types of tumor-altered DC function will be described, with empha-
sis on recent insights into the mechanistic bases for the inhibition of DC differentiation
from hematopoietic precursors, the altered programing of DC precursors to differentiate
into myeloid-derived suppressor cells or tumor-associated macrophages, the suppression
of DC maturation and activation, and the induction of immunoregulatory DC by tumors,
tumor-derived factors, and tumor-associated cells within the milieu of the tumor microen-
vironment. The impact of these tumor-altered cells on the quality of the overall anti-tumor
immune response will also be discussed. Finally, this review will also highlight questions
concerning tumor-altered DC function that remain unanswered, and it will address fac-
tors that have limited advances in the study of this phenomenon in order to focus future
research efforts in the field on identifying strategies for interfering with tumor-associated
DC dysfunction and improving DC-mediated anti-tumor immunity.
Keywords: dendritic cell, tumor, differentiation, maturation, activation, immunosuppression, tumor
microenvironment, immunotherapy
INTRODUCTION
Dendritic cells (DC) are critical regulators of host immune
responses that serve as a bridge between innate and adaptive
immunity. Following their differentiation from either myeloid
or lymphoid bone marrow-derived progenitors, DC populate
both lymphoid and peripheral tissues, where they are involved
in immune surveillance and control of immune reactivity in the
host. DC precursors may differentiate into a variety of special-
ized subsets that exhibit numerous immunoregulatory activities,
and the diverse functions of these cells are tightly linked to their
maturation and activation status (1). Immature DC are highly
phagocytic and function to sample both soluble and cell-associated
antigens (Ag) in host tissues. In the steady state, such imma-
ture DC either fail to elicit immune responsiveness to Ag they
have acquired (2), or they actively induce immune tolerance to
these Ag (3–6). On the other hand, stimulation of immature
DC by a variety of factors [including pathogen-associated mol-
ecular patterns, danger-associated molecular patterns (DAMPs),
inflammatory mediators, CD40L, etc.] induces the maturation
and activation of these cells, thereby converting DC into potent
stimulators of immune activation. Such DC upregulate expression
of costimulatory molecules, cytokines, and chemokines necessary
for the activation and recruitment of T lymphocytes and other
immune effectors into a response to eliminate the source of Ag
representing danger to the host (7–9).
In addition to their role in activation of immunity against for-
eign pathogens, DC have also been shown to be critical players in
the induction of anti-tumor immune responses (10–12). The role
of DC in eliciting such responses is highlighted by studies demon-
strating immunologic ignorance of tumors under conditions in
which cross-presentation of tumor Ag by DC is precluded (13–
17). However, despite the ability of DC to elicit tumor Ag-specific
T lymphocyte responses, in many cases these responses are dys-
functional and ineffective in clearing the tumor (18–24). While
such immune dysfunction might result from direct suppression
of T cells by tumors or tumor-derived factors, it may also arise
indirectly from suboptimal stimulation or suppression of T cells
by tumor-altered DC. Tumor-altered DC function has now been
documented in many cancer patients and tumor-bearing animals
and ranges from influences of tumors on the differentiation of
www.frontiersin.org July 2013 | Volume 4 | Article 192 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hargadon Tumor-altered DC function
DC from hematopoietic precursors to effects on the behavior of
fully differentiated DC. These effects on DC and their precur-
sors can lead to accumulation in the tumor microenvironment
of a variety of cells that include myeloid-derived suppressor cells
(MDSC), tumor-associated macrophages (TAM), immature DC,
and immunoregulatory myeloid DC (mDC) and plasmacytoid DC
(pDC), each of which exhibit distinct phenotypic characteristics
(Table 1). The identification of such cells in cancer patients not
only has important prognostic value, but it also has significant
implications for (1) the induction of natural anti-tumor immune
responses and (2) the efficacy of immunotherapeutic strategies
that target endogenous DC in situ or that employ exogenous DC
as part of immunization maneuvers. Therefore, because of the
importance of DC differentiation, maturation, and activation in
dictating the immune stimulatory versus inhibitory activities of
these cells, interference with any of these processes by factors or
cells within the tumor microenvironment may greatly influence
the induction and maintenance of anti-tumor immune responses
in the host. This review will summarize the current knowledge
regarding tumor-altered DC function and its impact on anti-
tumor immunity, and it will highlight both recent advances in the
field as well as important questions that will need to be answered
as efforts are made to improve the quality of DC-mediated anti-
tumor immune responses and DC-based cancer immunotherapies
in the future.
TUMOR-ALTERED DIFFERENTIATION OF DC PRECURSORS
AND ACCUMULATION OF MYELOID-DERIVED SUPPRESSOR
CELLS AND TUMOR-ASSOCIATED MACROPHAGES WITHIN
TUMORS
Dendritic cells are specialized cells that differentiate from both
myeloid and lymphoid progenitors before acquiring their unique
functions as Ag presenting cells (APC), and a number of stud-
ies have described factors derived from both tumors and asso-
ciated cells within the tumor microenvironment that interfere
with DC differentiation from precursors, thereby contributing
to a loss of stimulatory APC activity in tumor-bearing hosts.
Soluble factors secreted by human renal cell carcinomas and pan-
creatic cancers, including IL-6 and M-CSF, have been shown to
block DC differentiation from CD34+ progenitors and promote
lineage commitment toward CD14+ monocytes that express lit-
tle to no MHC and costimulatory molecules and that fail to
induce allogeneic T cell proliferation in mixed leukocyte reaction
(MLR) assays (25, 26). Similar inhibition of CD34+ precursor
cell differentiation into DC has been attributed to tumor-derived
VEGF (27), and this blockade of DC differentiation is associated
with suppression of NF-κB activity in these cells (28). VEGF has
also been implicated in suppressing the differentiation of skin-
resident Langerhans cells in a murine fibrosarcoma model (29).
In addition to secreting cytokines that inhibit DC differentiation,
tumors may also secrete other factors that interfere with the devel-
opment of different subsets of DC. The gangliosides GD2 and
GM3 secreted by human and murine neuroblastoma cell lines
have been shown to inhibit differentiation of DC from CD34+
progenitors (30), and human melanomas secrete GM3 and GD3
gangliosides that not only inhibit DC differentiation from mono-
cytic precursors but also induce apoptosis of monocyte-derived
Table 1 | Phenotypic characteristics of tumor-associated DC and
populations derived from DC precursors.
Cell population Cell surface markers Soluble proteins
Immature DC CD11chigh, CD80−/low, CD86−/low,
MHC class I/IIlow
Mature/activated
mDC
CD11chigh, CD80high, CD83,
CD86high, MHC class I/IIhigh
IL-12p70
MDSC CD11b, Gr-1 (mice) Arginase I
CD11b, CD14−/+, CD15, CD33,
MHC class II-/low (humans)
iNOS
ROS
IDO
TAM (M2-like) CD11b, CD14, CD68, CD115,
CD163, CD204, CD301, CD312,
F4/80
VEGF
HIF
TGFβ
IL-10
Arginase I
ROS
Regulatory mDC CD11chigh, CD40low, MHC class
IIlow, B7-H1high, B7-DChigh
Arginase I
IL-10
TGFβ
pDC CD11clow/int, CD19, B220/CD45R,
BDCA-4, MHC classIIlow
IFNα
Regulatory pDC CD11clow/int, CD19, B220/CD45R,
BDCA-4, MHC classIIlow, ICOS-L
IDO
DC (31, 32). Likewise, cyclooxygenase-1 (COX-1)- and COX-
2-derived prostanoids present in primary tumor-derived super-
natants from several freshly isolated human tumor types block
DC differentiation as well (33), and the source of these suppres-
sive mediators may be not only tumor cells themselves but also
stromal cells within the tumor microenvironment, as stromal cell-
derived prostaglandin-E2 (PGE2) was recently shown to inhibit
the differentiation of both bone marrow- and monocyte-derived
DC (34). Regardless of the mechanism of inhibition, the loss of
APC function associated with suppressing DC differentiation may
significantly limit the induction of anti-tumor immune responses
and contribute greatly to tumor immune escape.
In addition to the inhibitory effects of tumor-derived and
tumor-associated factors on DC differentiation that preclude the
development of cells with APC function, there is an abundance
of data documenting how these factors can also alter the dif-
ferentiation program of DC precursors and promote the accu-
mulation of immature myeloid cells with immunosuppressive
function (Table 2). These MDSC, characterized by expression of
CD11b and Gr-1 in mice and a number of cell surface markers in
humans (Table 1), are associated with various cancer types and
have been recovered at high levels from both tumors and tumor-
draining lymph nodes (35–38). Their induction may be driven by
a number of factors released by tumors and tumor-associated cells,
including VEGF (39), TGFβ (40), IL-1β (41), IL-13 (42), GM-CSF
(43), prostaglandins (44), reactive oxygen species (ROS) (45), and
components of the complement system (46). Differentiation into
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Table 2 | Mechanisms of immune suppression by MDSC.
Suppressive mediator Cellular target Impact on target
Reactive oxygen species T lymphocytes ↓ IL-2, ↓ proliferation,
↑ apoptosis
IDO CD8+ T lymphocytes Anergy
CD4+ T lymphocytes Induction of Tregs
Arginase I T lymphocytes ↓ CD3ζ chain
↓ Proliferation
Expansion of Tregs
TGFβ CD4+ T lymphocytes Induction of Tregs
NK cells Anergy
↓ NKG2D
↓ IFNγ
↓ Cytotoxicity
CCL3, CCL4, CCL5 CD4+ Tregs Recruitment to
tumor
IL-10 Macrophages ↓ IL-12
??? DC ↓ Phagocytosis
↓Maturation
↓Migration
↓T cell stimulation
???, unidentified factor(s).
MDSC is associated with hyperactivation of STAT3 (39, 47, 48) and
is accompanied by acquisition of a number of immunosuppres-
sive properties. In a murine sarcoma model, MDSC suppression
of Ag-specific CD8+ T cell responses required direct cell–cell con-
tact via TCR/MHC class I and was mediated by release of ROS
(49–51). Similarly, MDSC lines generated from mice bearing ade-
nocarcinomas exhibit nitric oxide-mediated suppression of IL-2
signaling in activated T cells. In this model, nitric oxide production
by MDSC required direct contact with, and IFNγ secretion by, the
activated T cell, and this nitric oxide inhibited T cell proliferation
and induced T cell apoptosis (52, 53). More recently, the increased
production of ROS by MDSC was shown to be the result of upreg-
ulated NADPH oxidase activity in these cells in several different
murine models and in head and neck cancer patients (54). MDSC
have also been shown to induce T cell tolerance through release
of indoleamine 2,3-dioxygenase (IDO) and arginase I, enzymes
involved in degradation of tryptophan and arginine, respectively
(55, 56). In regard to the latter, tumor-derived COX-2 can medi-
ate PGE2 signaling in MDSC, thereby triggering overexpression
of arginase I in these cells (57). In both murine models and can-
cer patients, tumors are enriched in arginase I-producing MDSC,
and arginine metabolism in the tumor microenvironment leads
to downregulation of CD3ζ chain and suppression of proliferative
capacity in both CD4+ and CD8+ T cells (58, 59). Interestingly,
recent studies evaluating the abundance and activity of MDSC in
tumors, tumor-draining lymph nodes, and peripheral blood of
cancer patients have shown that both the frequency and arginase I
activity of these cells correlates with the clinical stage of the tumor,
thus suggesting a critical role for these immunosuppressive cells
in disease progression (60, 61).
In addition to the direct tolerization of anti-tumor T lympho-
cyte responses by MDSC, these cells are also known to induce the
development of regulatory T cells (Tregs) that can also suppress
T cell activation. In this light, MDSC-derived TGFβ not only sup-
presses cytolytic activity of T lymphocytes (42), but it has also
been demonstrated in the B16 murine melanoma model to pro-
mote expansion of CD4+ CD25+ FOXP3+ Tregs in both tumors
and tumor-draining lymph nodes (62). Others have reported
that tumor-infiltrating MDSC isolated from B16 melanomas also
express high levels of the chemokines CCL3, CCL4, and CCL5,
the ligands for the CCR5 chemokine receptor that is preferentially
expressed on Tregs (63). These results indicate that MDSC likely
also play a critical role in recruitment of expanded Tregs into
the tumor microenvironment. Additionally, TGFβ-independent
MDSC induction of Tregs has been reported in a B cell lymphoma
model, where expansion of preexisting natural Tregs required
Ag presentation and arginase I activity by MDSC (64). A link
between MDSC and Tregs has also recently been reported in a study
of breast cancer patients, where the presence of IDO-expressing
MDSC correlated with increased infiltration of Tregs into primary
tumors and lymph node metastases (56).
The immunosuppressive activities of MDSC extend beyond
regulatory effects on T lymphocytes as well. In a murine model of
gestation-enhanced metastasis of B16 melanoma, MDSC dimin-
ished the number and activity of NK cells (65). Likewise, in
both mammary carcinoma and hepatic tumor models, MDSC
suppressed NKG2D expression, IFNγ secretion, and cytotoxic
activity by NK cells (66, 67). In the hepatic tumor model, sup-
pression required direct cell–cell contact and was mediated by
membrane-bound TGFβ on MDSC, and this interaction caused
NK cells to be hyporesponsive to activating stimuli, indicating
that they had acquired an anergic phenotype. Similar findings
have been reported in patients with hepatocellular carcinoma,
where suppression of NK cell activity was dependent on MDSC
engagement of the NKp30 receptor on NK cells (68). MDSC
have also been shown both to impede the maturation and T
cell stimulatory capacity of DC (69) and to engage in cross-
talk with macrophages, leading to diminished IL-12 secretion by
macrophages and increased IL-10 production by MDSC (70). Such
alteration of cytokine secretion patterns has the potential to polar-
ize helper and cytotoxic T cells toward a type 2 response that is less
robust in its anti-tumor efficacy.
In addition to shifting the differentiation of myeloid precursors
away from DC lineage commitment and promoting development
of MDSC, tumors can also drive the differentiation of DC precur-
sors into other immunosuppressive cells of myeloid origin, most
notably TAM. Recently, these cells have been shown to descend
from both bone marrow-derived and splenic precursors, and some
populations are believed to reflect the culmination of MDSC dif-
ferentiation (71). Importantly, accumulation of TAM, particularly
those with an anti-inflammatory M2-like phenotype, correlates
with poor prognosis in patients with a variety of cancers (72–76).
TH2 cytokines, glucocorticoids, and growth factors present in the
tumor milieu are all known to induce M2-like macrophages (77),
and tumor-derived IL-10 has specifically been shown to inhibit
www.frontiersin.org July 2013 | Volume 4 | Article 192 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hargadon Tumor-altered DC function
DC differentiation from monocytic precursors and to promote
the development of TAM from these cells (78). Much like MDSC,
these TAM can suppress a variety of immune effectors and pro-
mote Treg suppressive functions through production of TGFβ,
IL-10, and arginase I (38, 58, 79, 80). They have also been shown
to induce T cell apoptosis by upregulating expression of B7-H1
(81), the ligand for the PD-1 receptor on T cells. Taken together,
the diverse effects exerted by TAM and MDSC on cells of both
the innate and adaptive immune systems contribute greatly to the
immunosuppressive nature of the tumor microenvironment, and
these phenomena highlight the role that tumor-altered differenti-
ation of DC progenitors into MDSC and TAM plays in promoting
tumor immune escape.
TUMOR-ASSOCIATED SUPPRESSION OF THE MATURATION
AND ACTIVATION OF DIFFERENTIATED DC
In addition to subverting anti-tumor immunity by altering the
differentiation of DC precursors and either preventing acquisi-
tion of APC function by these cells or inducing their development
into immunosuppressive MDSC or TAM, tumors may also inter-
fere with the maturation and activation of fully differentiated DC.
While in vitro studies have shown that the release of heat-shock
proteins by necrotic tumors triggers DAMP-mediated DC mat-
uration (82, 83), and the presence of mature tumor-infiltrating
DC correlates with the magnitude of anti-tumor T cell responses
and disease prognosis in cancer patients (84, 85), a number of
studies have described the accumulation of fully differentiated,
yet immature, DC in tumors as well (86–88). Although a lack of
mature DC in tumor tissue might reflect tumor-induced death
of these cells (31, 32, 89), this phenomenon does not explain
the accumulation of immature DC often seen in tumors. In
cases where immature DC are recovered from tumors, it is often
unclear whether the immature phenotype of these cells reflects
a simple failure of tumors to support DC maturation and acti-
vation or, alternatively, an active suppression of DC maturation
by tumors. One study demonstrated that administration of anti-
CD40 Ab to tumor-bearing animals leads to maturation of DC
capable of stimulating T cell activation (90), suggesting that the
tumor either fails to support DC maturation or that suppres-
sion of DC maturation by the tumor is a reversible process.
In support of the latter possibility, it has been shown that the
maturation of tumor-infiltrating DC is enhanced following dis-
sociation of DC from the tumor and overnight culture ex vivo,
demonstrating that the tumor had actively limited DC matu-
ration in vivo (91). Other studies have revealed that tumor-
infiltrating DC are refractory to some maturation stimuli but not
others, indicating that tumors can actively suppress DC matu-
ration but that in some cases this suppression can be reversed
under appropriate stimulatory conditions (92–94). Interestingly,
in a comparative study of melanoma patients exhibiting either
progressing or regressing metastases, DC isolated from patients
with progressive disease expressed significantly lower levels of
costimulatory molecules than those taken from patients with
regressing tumors. Furthermore, DC from patients with regress-
ing metastases induced robust T cell proliferation, while DC from
patients with progressing metastases induced T cell anergy (95).
Collectively, these data suggest that the context in which the
tumor is encountered by DC is likely to impact the quality of
their maturation, activation, and immunostimulatory capacity,
and they emphasize the need to understand the role of tumor-
derived factors and the tumor microenvironment in regulating
the function of tumor-associated DC.
The limiting number of DC that can be isolated from tumor-
bearing animals and cancer patients and the complex nature of the
cell types and soluble proteins present within the tumor microen-
vironment have made it difficult to gain mechanistic insights into
tumor-associated suppression of DC maturation in vivo. Ex vivo
experiments with monocyte-derived and bone marrow-derived
DC (BMDC) have been used as an alternative to in vivo studies
for evaluating the suppression of DC maturation by tumor cells
or tumor-conditioned media (96–98). Recent studies using these
and similar ex vivo models have shown that interference with the
HIF-1-induced COX-2/PGE2 and VEGF pathways in colon cancer
cells and knockdown of TGFβ expression in hepatocellular carci-
noma both restore DC maturation that is otherwise suppressed
by these tumors (99, 100). In another system involving a multi-
cellular tumor spheroid three-dimensional model of melanoma,
tumor-derived lactic acid was shown to suppress the production of
several proinflammatory cytokines, including IL-12, by monocyte-
derived DC and to limit the ability of these cells to induce T
cell proliferation (101). Importantly, though, because these ex
vivo systems often require differentiation of DC from progen-
itors in culture, it is often unclear from these studies whether
the effects observed stem from a direct influence of tumors on
DC or instead from an indirect action mediated by an influence
of tumors on other cells in the culture that have not differen-
tiated into DC. Therefore, to overcome the limitations inherent
with studying the influence of tumors on DC function in both
in vivo and ex vivo settings, DC lines that can be maintained as
highly pure populations in culture have been generated and are a
useful tool for in vitro studies aimed at understanding the basic
biology of these cells (102–105). Such lines have enabled direct
analyses of tumor/DC interactions, and it has recently been shown
that melanoma-derived factors suppress the LPS-induced matu-
ration of both the DC2.4 and JAWSII DC lines (106). In a related
study, a comparative analysis of multiple murine melanoma cell
lines demonstrated that the suppression of DC2.4 costimulatory
molecule and proinflammatory cytokine/chemokine expression
correlates with the tumorigenicity of the melanoma under study
(107), with the highly tumorigenic B16 melanoma exhibiting sig-
nificantly greater suppression than its poorly tumorigenic, chem-
ically mutated variant D5.1G4. These findings again point to a
potentially vital role for tumor/DC interactions in the regulation
of overall anti-tumor immunity and tumor outgrowth. It will
be interesting to evaluate differences in the profile of immuno-
suppressive mediators released by these particular melanoma cell
lines, as this analysis will identify potential candidate molecules
involved in the suppression of DC maturation and activation
by this cancer. While concerns have been raised that maneuvers
employed to immortalize DC lines may alter the maturation state
of these cells and their responsiveness to regulatory factors, many
of these lines do exhibit the characteristics of immature DC and
are responsive to traditional maturation stimuli (108–110). There-
fore, additional studies using these DC lines and other tumor
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systems can offer proof-of-principle data that tumors interfere
with DC maturation in a straightforward, cost-effective model,
and such investigations will provide further mechanistic insight
into tumor-associated suppression of DC maturation and acti-
vation. Furthermore, observations made in such in vitro systems
are likely to inform the design of experiments evaluating the role
of tumor-derived factors in the suppression of DC maturation
and activation in more physiologically relevant ex vivo and in vivo
settings. Collectively, use of these different models will increase
our understanding of tumor-induced suppression of DC func-
tion, and these insights will suggest immunotherapeutic strategies
designed to reverse or prevent this suppression and enhance the
immunostimulatory capacity of tumor-associated DC.
TUMOR-ASSOCIATED INDUCTION OF
IMMUNOSUPPRESSIVE REGULATORY DC
The suppression of DC maturation and activation by tumor cells
or factors within the tumor microenvironment has significant
implications for the induction of T cell immunity to tumors, as
immature DC are poor APC and do not efficiently stimulate T cell
activation. There is also now substantial evidence that tumors not
only suppress DC maturation but that they can also induce the
development of regulatory DC that actively display immunosup-
pressive activity themselves. In fact, recent studies have demon-
strated that progression of ovarian cancer from an immunolog-
ically controlled state to metastatic disease is accompanied by a
switch in the phenotype and function of tumor-associated DC.
Whereas DC isolated from ascites or draining lymph nodes of
early-stage tumor-bearing mice elicited robust T cell responses,
those isolated from mice with advanced disease induced minimal
T cell proliferation and suppressed T cell activation by immuno-
competent DC (111, 112). Immunosuppressive DC isolated from
late-stage tumor-bearing animals downregulated MHC class II and
CD40 expression but significantly upregulated the co-inhibitory
molecule B7-H1 and exhibited arginase I activity comparable to
that seen in MDSC. These immunosuppressive activities were
driven by tumor-derived PGE2 and TGFβ (112). Other studies
have also demonstrated tumor-induced upregulation of DC co-
inhibitory molecules, including both B7-H1 and B7-DC (10, 96),
as well as tumor-enhanced secretion of arginase I (113, 114) and
TGFβ (115) by DC that inhibit T cell effector function and pro-
mote Treg development, respectively. In both tumor-bearing mice
and prostate cancer patients, the expression of these and other
immunoregulatory molecules by tumor-associated DC resulted
from elevated expression of FOXO3 (116), a transcription factor
recently shown to mitigate DC stimulatory capacity (117). Addi-
tionally, inhibition of T cell effector activity by tumor-associated
regulatory DC has also been associated with increased IL-10 secre-
tion by these cells. A variety of soluble factors present in colorectal
tumor explant cultures, including VEGF and the chemokines
CCL2, CXCL1, and CXCL5, were shown to enhance IL-10 pro-
duction by DC (118, 119). Non-soluble mediators expressed on
colorectal carcinoma cells can contribute to this process as well, as
IL-10 production by DC was increased following engagement of
DC-SIGN by tumor-associated cell surface glycans (120). Likewise,
recombinant MUC1 mucins glycosylated in a manner equiva-
lent to those expressed on breast carcinoma cells and natural
MUC1 mucins in supernatants of human pancreatic carcinoma
cell lines both suppress IL-12 production and promote IL-10
production by monocyte-derived DC, and these regulatory DC
are poor stimulators of T cell proliferation and CTL activity but
potent inducers of T cell anergy and CD4+ Tregs (121, 122). IL-
10 production by tumor-associated DC that inhibit anti-tumor
T cell responses and promote tumor outgrowth has also been
reported to be induced by COX-2/PGE2 (123, 124). Similarly, in
a murine myeloma model, tumor-derived IL-6, IL-10, and TGFβ
were all shown to contribute to p38 MAPK signaling-mediated
effects on BMDC maturation that led to decreased production of
IL-12 and increased production of IL-10 by DC, and these cells
elicited poor tumor-specific TH1, CTL, and antibody responses
(125). Hyperactivation of MAPK signaling similarly inhibited IL-
12 production and TH1 stimulation by melanoma-altered DC,
though these effects were independent of IL-10, TGFβ, VEGF, and
PGE2 in tumor lysates (97). In addition to suppressing the devel-
opment of TH1-type immunity, other studies have shown that
melanoma, as well as breast cancer, triggers DC-mediated induc-
tion of TH2-like responses that promote tumor development (126,
127). Identification of factors produced by these tumors and their
role in MAPK hyperactivation in DC will be crucial to developing
strategies for skewing anti-tumor T cells toward type 1 responses
that are more efficient in mediating tumor rejection.
In addition to the regulatory DC activities described above,
which are largely associated with conventional mDC, a special-
ized subset of DC that develop immunosuppressive activity in the
context of many tumors is the pDC. IDO-expressing pDC can be
induced by tumor-derived PGE2 (128) and have been recovered
from tumor-draining lymph nodes of both melanoma-bearing
animals and cancer patients (129). These cells suppress CD8+ T
cell responses to Ag presented by the pDC themselves as well as to
those presented by third-party, non-suppressive APC. In addition
to inducing CD8+ T cell anergy, IDO production by pDC also pro-
motes the differentiation of CD4+ CD25+ FOXP3+ Tregs (130).
Interestingly, pharmacologic blockade of IDO leads to enhanced
IL-6 production by pDC that converts tolerogenic CD4+ Tregs
into TH17-like cells, and this conversion correlates with enhanced
CD8+ T cell activation and anti-tumor immunity (131). CD4+
Treg induction by pDC can also be mediated by engagement of
ICOS on T cells with ICOS-L on pDC, and ICOS-L+ pDC infil-
tration of tumors is associated with poor prognosis and disease
progression in both breast and ovarian cancer patients (132–134).
Tumors can also subvert immunity by regulating pDC production
of IFN-α, a type I IFN that functions as a “signal 3” cytokine for
CD8+ T cell activation (135) and that promotes the survival and Ag
retention of CD8α+ DC that cross-prime tumor-specific CD8+ T
cells (11). In clinical studies, tumor-associated pDC have been iso-
lated by magnetic activated cell sorting via BDCA-4 positive selec-
tion of lineage-negative enriched mononuclear cells obtained from
patient biopsies. In patients with aggressive breast cancers, these
pDC exhibit suppressed IFN-α secretion and are able to sustain
CD4+ Treg expansion (136), and the suppression of IFN-α pro-
duction by pDC has been attributed to tumor-derived TGFβ and
TNFαmediated-signaling in these cells (137). Finally,pDC isolated
from ascites of ovarian carcinoma patients have also been shown
to induce CD8+ Tregs that secrete high levels of IL-10 and suppress
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T cell proliferation (138). Altogether, these findings demonstrate
the complexity of the tumor microenvironment and its ability to
induce a variety of immunoregulatory activities in DC that impact
the function of multiple cell types involved in anti-tumor immune
responses (Table 3). Tumor-associated conversion of these poten-
tially immunostimulatory APC into suppressive cells is there-
fore a significant hurdle to the induction of effective anti-tumor
immunity that contributes greatly to tumor immune evasion.
IMMUNOTHERAPEUTIC STRATEGIES FOR INTERFERING
WITH TUMOR-ASSOCIATED DC DYSFUNCTION
The induction of DC dysfunction is a major impediment to the
activation and maintenance of successful anti-tumor immunity
(Figure 1). Indeed, in addition to its documented impacts on
anti-tumor T cell responses summarized herein, this phenomenon
may also explain the unaccounted for presence of dysfunctional
T cells associated with naturally generated immune responses in
other experimental animal models and cancer patients (18–24).
Additionally, tumor-associated DC dysfunction may limit the effi-
cacy of immunotherapeutic strategies that rely on the activity of
DC in situ to stimulate anti-tumor immunity, and it may there-
fore explain the lack of success observed thus far with many DNA-,
peptide-, and protein-based immunization maneuvers that require
endogenous DC to process and present tumor Ag to specific T
cells (139–143). Even the quality of responses elicited following
immunization with previously activated, exogenous DC may be
compromised by an influence of tumor-associated factors on DC
function. Importantly, though, insights into the mechanistic bases
for tumor-associated DC dysfunction have informed the design
of novel DC-based cancer immunotherapies, and many of these
strategies have enhanced the T cell stimulatory capacity of DC
and led to induction of more robust and efficacious anti-tumor
immune responses.
Several strategies have been employed to promote DC differ-
entiation from hematopoietic precursors and prevent the accu-
mulation and suppressive activities of tumor-associated cells of
myeloid origin. For instance, both IL-4 and IL-13 were shown
to prevent renal cell carcinoma-induced blockade of DC differ-
entiation (144). Similarly, administration of the anti-VEGF Ab
bevacizumab to patients with lung, breast, and colorectal carci-
noma led to a decrease in the frequency of MDSC and enhanced
the T cell stimulatory capacity of DC (145). Abrogation of MDSC
immunosuppression can also be achieved by exposure of these
cells to all-trans retinoic acid, which induces the differentiation
of MDSC isolated from a number of murine tumors and renal
cell carcinoma patients into mature immunostimulatory DC (146,
147). Others have demonstrated that interference with STAT3-
mediated-signaling reverses immune suppression by MDSC and
enables differentiation of these cells into mature DC (39, 61).
One study also showed that interference with both STAT3 and
p38 MAPK signaling pathways in monocyte progenitors fur-
ther improved the quality of tumor-associated DC, blocking the
inhibitory effects of tumor-derived factors on DC differentia-
tion from these progenitors and skewing the IL-12/IL-10 cytokine
profile of the resulting DC toward a TH1-promoting phenotype
(148). Based on these data, it is not surprising that vaccina-
tion with exogenous, STAT3-depleted DC was shown to enhance
Table 3 | Induction and suppressive activity of tumor-associated
regulatory DC.
Tumor-derived factor Regulatory
DC activity
Impact on
host immunity
TGFβ, PGE2 ↓MHC II ↓T cell proliferation
↓ CD40 ↓T cell effector function
↑ B7-H1
↑ Arginase I
VEGF ↑ IL-10 ↓T cell effector function
CCL2, CXCL1, CXCL5
Glycans
COX-2/PGE2
MUC1 mucins ↓ IL-12 ↓T cell proliferation
↑ IL-10 ↓ CTL activity
T cell anergy
↑ CD4+ Tregs
IL-6, IL-10, TGFβ ↓ IL-12 ↓TH1 polarization
↑ IL-10 ↓ CTL activity
↓ Ab response
??? ↑TGFβ ↑ CD4+ Tregs
PGE2 ↑ IDO by pDC CD8+ T cell anergy
↓ IL-6 by pDC ↑ CD4+ Tregs
TGFβ, TNFα ↓ IFNα by pDC ↑ CD4+ Tregs
↑ CD8+ Tregs
??? ↑ ICOS-L by pDC ↑ CD4+ Tregs
???, unidentified factor(s).
anti-tumor CD8+ T cell responses and improve control of tumor
outgrowth (149).
In addition to strategies that interfere with the development and
suppressive activities of tumor-associated myeloid cells, several
approaches are being explored for improving the quality of fully
differentiated DC in the context of tumors as well. In vivo admin-
istration of nanoparticles carrying immunostimulatory miRNA
converts endogenous immunosuppressive DC into cells capable
of activating robust anti-tumor responses that inhibit progression
of established ovarian cancers (150). Moreover, supplementation
of stimulatory cytokines whose expression is often suppressed
in tumor-associated DC, such as IL-12 and IFNα, can enhance
T cell effector function elicited by endogenous DC (151, 152).
Significant efforts have also been made to optimize exogenous
DC-based cancer immunotherapies. Several studies have investi-
gated various maturation protocols for exogenous DC in order
to best promote the immunostimulatory capacity and vaccine
efficacy of these cells (153–156). One group has reported that
treatment of PBMC-derived immature DC with various combina-
tions of cytokines and inflammatory stimuli, namely LPS+ IFNγ,
LPS+ IFNγ+ IL-1β, and LPS+ IFNγ+ IL-1β+TNFα, results in
no discernible difference in DC expression of costimulatory mole-
cules or IL-12 (153). On the other hand, substantial differences
in DC maturation have been observed following exposure of
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FIGURE 1 | Summary of tumor-altered DC function. Illustrated here are the
mechanisms by which tumors alter DC function and the processes by which
these altered cells impact host anti-tumor immunity. Tumors secrete a variety
of factors that can: (1) inhibit differentiation of DC from precursors, (2) induce
differentiation of DC precursors into immunosuppressive MDSC or TAM, (3)
suppress maturation, activation, and stimulatory APC function of already
differentiated DC, and (4) induce development of immunosuppressive
regulatory DC.
immature DC to a mixture of various other inflammatory media-
tor/cytokine cocktails. Stimulation with lipid A and IFNγ resulted
in significantly higher DC expression of costimulatory mole-
cules and IL-12 than stimulation with a combination of TNF-α,
IFN-α, IFN-γ, IL-1β, and poly(I:C) or a combination of TNF-
α, IFN-γ, IL-1β, and CL097 (156). Still others have evaluated
DC maturation following exposure to tumor lysates. PBMC-
derived DC treated with lysates from heat-shocked melanoma
cells exhibited robust maturation and immunostimulatory capac-
ity, as these cells were capable of cross-presenting melanoma-
associated Ag and inducing anti-tumor CD8+ T cell responses
(154). Importantly, heat-shocking of melanoma cells induced
membrane translocation of CRT and expression of HMGB1, and
the maturation of immunostimulatory DC in this study was
dependent on their recognition of these tumor-derived “danger
signals.” It has also recently been shown that TNFα can aug-
ment tumor lysate-induced DC maturation (155). In addition to
investigating strategies for optimal induction of DC maturation,
many researchers have employed strategies to block the suppressive
effects of tumor-derived factors on exogenous DC. In this light,
DC genetically engineered to secrete aVEGF/vascular permeability
factor decoy receptor that neutralizes soluble VEGF and precludes
signaling in DC resulted in increased expression of costimula-
tory molecules and proinflammatory cytokines/chemokines by
DC and improved CTL activity and anti-tumor immune control
in a murine colon cancer model (157). Similar improvements in
the efficacy of an exogenous DC vaccine were observed following
neutralization of tumor-derived TGFβ (158). Alternatively, other
approaches for enhancing exogenous DC-induced anti-tumor
immune responses aim at blocking either the immunosuppres-
sive mediators expressed by tumor-altered DC or the targets of
these mediators expressed on other immune cells. In a murine
model of breast cancer, siRNA-mediated silencing of IDO in
vaccinating DC enhanced the ability of these cells to stimulate
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T cell proliferation and CTL effector function, decreased the
induction of CD4+ CD25+ FOXP3+ Tregs, and led to enhanced
control of tumor outgrowth (159). Similarly, immunization with
IL-10-deficient DC conferred enhanced protective and thera-
peutic immunity against a murine hepatocellular carcinoma
(160). Furthermore, DC genetically engineered to interfere with
immunomodulatory receptors expressed on endogenous immune
cells, such as CTLA-4 on effector T cells and GITR on Tregs, can
enhance the overall immunogenicity of these cells as well (161,
162). Improved anti-tumor immunity has also been observed for a
DC-based vaccine administered in combination with anti-CTLA-4
Ab and Treg-depleting anti-CD25 Ab (163). Likewise, adminis-
tration of neutralizing Ab that interferes with the B7-H1/PD-1
pathway improved the efficacy of a DC/tumor fusion vaccine in
multiple myeloma patients (164). Finally, it is also possible to
improve the efficacy of both exogenous and endogenous DC-based
vaccines by transducing DC either ex vivo or in vivo with viral
vectors that encode immunostimulatory molecules. A number of
studies have reported improved anti-tumor immunity when this
approach was used to drive expression of CD80/CD86 costimula-
tory molecules (165, 166) or IL-12 (167) by DC. Collectively, these
strategies highlight the advances made in tumor immunotherapy
as our understanding of tumor immune suppression and eva-
sion has evolved over the last several years. As additional insights
into tumor-altered DC function are gained, optimization of these
current immunotherapies and development of novel strategies for
enhancing anti-tumor immune responses will further improve the
efficacy of DC-based cancer vaccines.
CONCLUSION
Tumor immunosurveillance is now a well-documented phenom-
enon whereby host immune cells and effector molecules function
to recognize and eradicate developing tumors in the body. At the
heart of this process are DC, innate immune cells that function to
acquire tumor Ag through phagocytosis, activate adaptive immu-
nity against these specific tumor Ag, and recruit immune effectors
to the site of the tumor for immunologic destruction of these
transformed cells. However, one of the hallmarks of cancer growth
is immune evasion, and tumor cells may evolve a number of escape
mechanisms during their progression that subvert immunosur-
veillance. A significant contributor to tumor immune evasion is
the alteration of DC function by tumors and associated factors
present in the tumor microenvironment. As discussed, such alter-
ation of DC function may include effects on the differentiation
of DC from bone marrow-derived precursors, suppression of the
maturation and activation of already differentiated DC, and the
induction of immunosuppressive regulatory DC that inhibit anti-
tumor immune responses. Over the last several years, significant
efforts have been made to gain mechanistic insights into these
processes of tumor-altered DC function. These findings have in
turn led to the development of several immunotherapeutic strate-
gies for improving the function of tumor-associated DC. Still,
much remains to be learned about the processes by which tumors
impact the function of DC and how such altered DC influence
the quality of other immune effectors. As this field moves for-
ward, it will be important to increase our understanding of factors
that contribute to tumor recognition by DC and to identify addi-
tional tumor-associated DAMPs and inflammatory stimuli that
promote optimal maturation and activation of immunostimu-
latory DC. Additionally, a better understanding of how tumor
microenvironmental factors impact the quality of DC differentia-
tion, maturation, and activation will suggest new possibilities for
interfering with the suppression of these processes by tumors. Such
knowledge will enable the optimization of current, and the devel-
opment of novel, DC-based immunotherapies that aim to improve
the quality and outcome of host anti-tumor immune responses.
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